





# Janssen Belgium

Imagine the Possibilities.





Our main concern, in everything we do, is patient care. With our 4,600 employees in Belgium, we aim for breakthrough solutions in the prevention, interception and treatment of diseases.

# Welcome

---

**Welcome to Janssen. Janssen Belgium hosts the largest site of Johnson & Johnson outside of the United States and the largest R&D center for small molecules. We are thrilled to be able to share with you the excitement of our endless pursuit to meet areas of great unmet medical need.**

Our people are tackling the limits of medical science every day, with passion, scientific rigor, and the willingness to take risks and collaborate. The development of medicines that have the potential to alter the course of disease is a complex process that requires a combination of the best minds with the best technologies — and the necessary infrastructure and culture to support both.

We are proud to have in Belgium a unique innovation ecosystem covering the complete life cycle of drug development. From the early start of basic research, over production, commercial and supporting services, market access and the distribution of medicines. We control the entire pharmaceutical cycle which makes us unique in the pharmaceutical world. We combine our strengths in pharmaceuticals and diagnostics, import ideas, technologies, and talent from our open innovation partners, and collaborate closely to understand market needs and create solutions that transform lives.

In this quest for innovation, people are our most important resource. We focus on a unique entrepreneurial culture that values and recognizes excellence — and breeds it — both within the organization and in the external community. With more than 4,600 employees and new state-of-the-art facilities, Janssen Belgium is a key driver of growth for Johnson & Johnson.

Discover how we work towards our goals, utilizing a strong sense of mission, nurturing a creative and productive culture, living the words of Our Credo, and creating value through innovation.

Innovation is our collective aspiration to be the best we can in terms of healthcare solutions, leadership, science and technology, people, teamwork, collaboration, passion and creativity.



**SONJA WILLEMS**  
Managing Director, Janssen Benelux



**TOM HEYMAN**  
CEO, Janssen Pharmaceutica



**Together, we are looking  
at a future where patients  
and their families have a  
new sense of hope.**

# About Janssen

**Who is Janssen? We're more than 40,000 people working hard to prevent, treat, cure and stop some of the most devastating and complex diseases of our time. From heart disease to HIV, Alzheimer's disease to cancer, we are committed to issues that touch everyone's life.**

## Our Mission and Vision

Our mission is to transform individual lives and fundamentally change the way diseases are managed, interpreted, and prevented. We believe that challenging something is the best way to change it. So every day, in more than 150 countries, we bring cutting-edge science and the most creative minds in the industry together to think differently about diseases. We aim not only to innovate but also to empower people with the tools they need to make informed decisions and achieve the best possible results for their health.

We are looking at a future where the world of healthcare will be challenged by informed and empowered patients. We work for change that will improve access to medicines: the best available treatment at an affordable price. That's why we at Janssen strive to provide access to effective and affordable medicines and related healthcare services to the people who need them.

## Our Partners

The world is our lab, and we seek medical breakthroughs wherever they occur. Our approach to collaboration helps drive our success. By partnering with academic researchers, governments, patient groups, healthcare professionals, and others, we are finding answers to some of the most devastating diseases of our time.

We work with our partners at every stage, from early discovery to market access and patient education. To ensure that we can deliver our commitments to the people, customers and investors who rely on us, we work side-by-side with healthcare stakeholders, bringing together our experts with the top minds in the field. Together, we are looking at a future where patients and their families have a new sense of hope. We are working toward a common goal – a healthy outcome for each patient.

Because ultimately, solving complex problems is about taking a different approach. It's about how we work and who we work with. It's about finding the best solutions — and then taking it one step further to help bring those solutions to the people who need them most, wherever they live. We are Janssen and we collaborate with the world for the health of everyone in it.

## OUR FOCUS AREAS

We are developing treatments for patients in five important therapeutic areas of healthcare:



Neuroscience



Infectious Diseases  
and Vaccines



Immunology



Oncology



Cardiovascular  
and Metabolism

# A strong heritage in Belgium

**Janssen Belgium is a member of the Johnson & Johnson Family of Companies. As a place of historical importance, we have been focusing on research & development of innovative medicines for more than 50 years. Janssen continues to build on the legacy of Dr. Paul.**

## 1926 Entrepreneurial genes

Founder of the company, Dr. Paul Janssen was born 12 September 1926 in Turnhout. His father Constant was a successful general practitioner at the time, but had set his heart on creating his own company. In 1927, he started importing and distributing Richter products, and, in 1934, he founded the N.V. Produkten Richter. The family business concentrated on the distribution of Richter products in Belgium,



the Netherlands and the Belgian Congo. Richter is still a successful Hungarian pharmaceutical company, which launched Janssen products onto the markets of several Eastern European countries, until Janssen established its own network of affiliates in this region. Constant Janssen introduced products of his own making onto the market for some time after the Second World War, under the name of Eupharma.

## 1948 A passion for science

After his secondary education at the Sint-Jozefcollege in Turnhout, the young Paul Janssen started studies in Namur, at the Faculté Notre Dame de la Paix. The physics, biology and chemistry courses that he attended stimulated his scientific passion even more. Following his conviction that there must be a link between the chemical structure of a molecule and its medicinal effect, he took up medicine studies at the University of Leuven in 1945. He moved to the United States in 1948 in order to become acquainted with modern drug research in private laboratories. He graduated as a General Practitioner

at the Gentse Rijksuniversiteit (Ghent University) in 1951, and was initially employed as an assistant by several renowned professors in Ghent and Cologne. A great academic career lay ahead of him, ready for the taking, but he wanted to realize his dream and established his own research laboratory in 1953.

## 1953 First employees

Together with his first employees, Dr. Paul started work on the third floor of his parents' company at the Stationstraat in Turnhout, in 1953. He was keen to discover the effect that a chemical substance could have on a living organism. His goal was to create chemical compounds with the intention of patenting them as soon as possible, in order to finance his own research with the proceeds. A Dutch physician in a company based in Amsterdam that specialized in this area examined Dr. Paul's first compounds with regard to their effectiveness and safety. Together with his first employees, he laid the foundation for his own pharmaceutical company in this way.



## 1955 Rapid successes

Dr. Paul's first major discovery was ambucetamide, a drug used to relieve menstrual pains, which was launched in 1955. Soon afterwards, several well known American companies took a number of his first drugs under license, including the painkiller dextromoramide (PALFIUM), which attracted a lot of media attention. The anti-diarrheal drug diphenoxylate (REASEC), very successful in the American market under the brand name



LOMOTIL, even traveled to the moon with the Apollo astronauts in 1969. What was Dr. Paul's key to these early successes? His 'positive dissatisfaction', his unwillingness to accept the ultimate limitations of science, his neverchanging openness to new developments and the opportunities that reveal themselves.



## 1957 From Turnhout to Beerse

In 1956, the family company was renamed N.V. Laboratoria Pharmaceutica Dr. C. Janssen. Because the premises were soon bursting at the seams, Dr. Paul moved to Beerse with thirty employees in 1957. The N.V. Research Laboratorium Dr. C. Janssen consisted of a department for synthetic chemistry, a pharmacological laboratory, an analysis laboratory, offices, and areas where test animals were held (mice and rats). Subsequent years saw a rapid and successful expansion at the new campus, a former military training site that was converted into the first industrial site by the municipality of Beerse.

## 1958 Revolution in psychiatrics

With the synthesis of haloperidol (HALDOL) at the end of the fifties, more specifically in 1958, Paul Janssen launched a true revolution in how mental illness had been treated up to then. Instead of putting patients in straitjackets and administering electroshocks to them, psychotic patients could now be freed from their hallucinations and delusions, and be made ready to take up a virtually normal life in society again. The quest for even better variants resulted in numerous successful Janssen antipsychotics in the years that followed. Thanks to innovative technologies, injectable and long-acting formulations, which are user-friendly and therefore even more effective, were also created.



## 1960 Powerful painkillers for people & animals

What haloperidol brought about in psychiatric care, fentanyl (FENTANYL-JANSSEN) repeated in anesthesia. After 55 years, this product, which was first synthesized in 1960, is still the most widely used analgesic in the world. In recent years, the product has been particularly successful in the form of a patch that is used very effectively in the battle against chronic pain, especially in cancer patients. Sufentanil (SUFENTA) is 1,000 times more powerful than morphine, and can therefore be used for complex surgical procedures, such as heart transplants. Bill Schroeder, the second man to receive an artificial heart during an operation that lasted six hours in 1984, was anesthetized with sufentanil. Another area where powerful Janssen anesthetics are often used is for the transportation of animals between wild parks, such as in Africa.

## 1961 Janssen part of Johnson & Johnson

In the early sixties, the American company Johnson & Johnson expressed an interest in acquiring N.V. Laboratoria Pharmaceutica Dr. C. Janssen. In Dr. Paul's opinion, this was an excellent chance to guarantee the future of his fast-growing company. In 1961, the two research companies in Turnhout and Beerse, the export company Bepharex and the two Janssen affiliates in Tilburg and Düsseldorf were fully integrated into Johnson & Johnson. At that time, a successful businessman from Turnhout, Frans Van den Bergh, was Chairman of the Board. He led the negotiations with Johnson & Johnson together with Paul Janssen, and brought them to a successful conclusion. It was also Van den Bergh who suggested the name Janssen Pharmaceutica.



# “What’s new?”

---

Dr. Paul Janssen (1926-2003)

## 1970 Pioneering drugs

Several employees of Dr. Paul Janssen had already gained many years of practical experience in the former Belgian colonial territories of the Congo, Rwanda and Burundi. In Beerse, they concentrated on finding promising molecules in the field of parasitology, pharmacology, mycology and neurology, for which the expertise they obtained in Africa was an excellent help. The number of employees expanded rapidly: from 377 in 1961 to 807 in 1970 and 1,734 in 1980. Two new departments, Veterinary Medicine (1964) and Plant Protection (1972), were created. It is therefore not surprising that numerous pioneering medicines saw the light of day in the following years, including drugs that are now well-known against moulds, worms, diarrhea, stomach upsets and vomiting, psychosis, and medication for use in anesthetics.

## 1979 Worldwide expansion

In the seventies and eighties, Janssen Pharmaceutica developed a worldwide network of companies. The Janssen affiliates in England (1971), Japan (1978), the United States (1979) and China (1985) were established in this way, while research centers also became active in the United States, England, Germany, France and Spain. A special success story was the opening of a fully-owned pharmaceutical plant in Xian (China) at the end of the eighties, with which Janssen made history in this immense country. In 2007, India was added to this list, following the opening of an Analytical & Pharmaceutical Development Center in Mumbai. In this way, Janssen could progress along its own successful course for many years within the global family of companies Johnson & Johnson.

## 1995 Development at home

The global expansion of the company also propelled the expansion at home into a higher gear. Janssen opened a first Chemical Production plant (Plant 1) in 1975, at the new company site in Geel. Another three production plants were added later (Plant 2 in 1977, Plant 3 in 1984 and Plant 4 in 1995), as well as a high-tech pilot plant for chemical development (2009). In 1992, Janssen Biotech was founded in Olen for the production of pellets, and a completely new pharmaceutical plant (Plant 1) was constructed on the Beerse campus, next to the existing factory, in 1996. The financial center and Janssen Belgium were accommodated in a modern building on the new company site Beerse 2 (2002). The Dr. Paul Janssen Research Center was opened at the Beerse 1 site in 2004, where also the Drug Safety Evaluation Center was inaugurated one year later.

## 2003 The key to success? Innovation!

Inspired by Dr. Paul, who passed away suddenly on 11 November 2003, devoted Janssen employees continued their search for innovative drugs which resulted in several key products in the last 10 years. Several Janssen medicines, including drugs fighting psychoses (1996), cancer (2006), hepatitis C (2011), psoriasis (2012) and tuberculosis (2015) won the Prix Galien, which can be compared to a Nobel Prize for scientific innovation. The annual presentation of the Dr. Paul Janssen Award for Biomedical Research was established by Johnson & Johnson as a tribute to our founder Dr. Paul Janssen. This prestigious award aims to stimulate worldwide innovative research work by highly passionate and creative international scientists.

## 2010 Janssen, Pharmaceutical Companies of Johnson & Johnson

Since 2010, all Johnson & Johnson pharmaceutical activities continue under one name and logo: Janssen Pharmaceutical Companies of Johnson & Johnson. Today Janssen is one of the most innovative pharmaceutical companies in the world.

# Janssen Belgium

---

Janssen Belgium is an inspiring place to work and collaborate on innovative solutions for the health of people all over the world. The international campus with a unique entrepreneurial spirit brings together 4,600 employees of thirty nationalities. Our efforts in Belgium focus on small molecules and diagnostics in important therapeutic areas.



## Unique ecosystem covering complete drug development life cycle

Janssen Belgium has sites in Beerse (Beerse I and II), Geel, Olen, Diegem, La Louvière and Merksem. Together these organizations discover, develop and produce medicines and therapeutic solutions for patients worldwide. From the early start - basic research on new medicines - production, commercial and supporting services to distribution of medicines. This is how Janssen Belgium controls the entire pharmaceutical cycle, which makes the company unique in the pharmaceutical world.

The integrated environment gives our people the chance to experience many different aspects of drug development throughout their career. In recent years, millions have been invested to ensure our people have access to strong core facilities and the most modern infrastructure available that fulfills the strictest requirements with regard to quality and safety of our employees.

## Unique in the pharmaceutical world

Janssen Belgium has excellent expertise in the field of neuroscience, oncology and infectious diseases. Every day the company and its partners are dedicated to the discovery and development of a new generation of small molecules for the fight against schizophrenia, depression, pain control, dementia, hepatitis, HIV, different types of cancers,... With state-of-the-art production facilities, we play a central role in the global Supply Chain. Everyday our teams are dedicated to make reliable medicines available, quickly and efficiently, to patients around the world.

## Discover the campus experience

Janssen Belgium is a great place to work, grow, collaborate across disciplines and thrive in a diverse, international and welcoming environment. We are fortunate to have world-class facilities and an environment to cultivate great dynamism and vibrancy in a robust and engaged community, we enrich the lives of our people and contribute to a vibrant community that develops leaders in all fields—people determined to have a positive impact.

## Booming life sciences in Belgium

Belgium is a world-class player in human healthcare. World leading pharmaceutical companies with bases in Belgium include GSK, UCB, Baxter, Janssen, Amgen, Genzyme, MSD, Pfizer and Roche. Janssen plays a key role as a major contributor to the Belgian life sciences industry.

The development of the life sciences sector in Belgium has created several biotechnology clusters comprising universities, companies and organizations active in the life sciences industry. Belgium has always proved to be a region that shows new ingenious ways of putting science to good use for the benefit of millions of people worldwide.





## Immunology

Rheumatoid arthritis, psoriasis and immune diseases



## Infectious Diseases and Vaccines

HIV/AIDS, hepatitis C, tuberculosis and flu



## Oncology

Multiple myeloma, breast, lung, prostate, colorectal cancers



## Neuroscience

Schizophrenia, pain, cognitive disorders and dementia



## Cardiovascular and Metabolic Diseases

Heart disease, diabetes and obesity



Part of the fastest-growing pharmaceutical company in the United States, Europe and Japan.

**WE ARE UNITED**  
by one mission: to discover and develop innovative medicines that reduce patients' suffering, and to provide an answer to the most important unmet medical needs of our time.  
**That is what brings us together and drives us.**



+40,000  
EMPLOYEES

4,600  
IN BELGIUM



Janssen  
Belgium



Our 6 locations

- › Beerse
- › Diegem
- › Geel
- › Olen
- › Merksem
- › La Louvière

**MOST ATTRACTIVE  
private employer  
IN BELGIUM<sup>2</sup>**

#1  
IN R&D PRODUCTIVITY

14  
NEW TREATMENTS  
IN 6 YEARS

8  
PRODUCTS ON  
THE WHO LIST  
OF ESSENTIAL  
MEDICINES

5  
BREAKTHROUGH  
THERAPY  
DESIGNATIONS

INVESTMENT IN  
10  
NEW MEDICINES FOR  
REGISTRATION BY 2019<sup>1</sup>

25  
NEW IMPORTANT  
INDICATIONS BY 2019<sup>1</sup>



Top 10  
BELGIAN COMPANIES  
WITH BEST REPUTATION<sup>3</sup>

Our Medicines  
[www.janssen.com/belgium](http://www.janssen.com/belgium)

<sup>1</sup> Johnson & Johnson Pharmaceutical Segment to Continue Driving Above-Industry Growth with Plans to File More than 10 New Products by 2019, Each with Potential to Exceed \$1 Billion in Revenue <http://www.investor.jnj.com/releasedetail.cfm?ReleaseID=914070>

<sup>2</sup> Randstad 2015

<sup>3</sup> RepTrak® Belgium 2015



# Patient Needs



Internal and External Innovation




Research & Development

Janssen Research & Development in Belgium forms, together with the research centers in other European countries (France, Netherlands, Spain and UK), the United States and Asia Pacific, one global organization. R&D Belgium hosts 1,800 employees from 30 different nationalities and is the largest R&D center of Johnson & Johnson for small molecules. Our focus is to discover, develop and deliver differentiated medicines. Our researchers are continually searching for innovative molecules and research efforts have already yielded numerous groundbreaking drugs in 3 therapeutic areas: Oncology, Neuroscience and Infectious Diseases. Our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide.



Supply Chain

Every day people in the Janssen Supply Chain are dedicated to make reliable medicines available, quickly and efficiently, to patients who need them, all over the world. Two state-of-the-art production facilities are responsible for supplying our medicines to markets around the world. With quality as our primary focus, our mission is to deliver affordable medicines to anyone, anywhere, any day.



Supporting Services

— ALL PHARMACEUTICAL ACTIVITIES —  
from Discovery to Market Access

ON ONE CAMPUS

## CHEMICAL SUPPLY CHAIN GEEL

Janssen Supply Chain Geel is a chemical production site where we produce over 50 different Active Pharmaceutical Ingredients (API) for 4 different therapeutic areas: Cardiovascular, Infectious Diseases, Neuroscience and Oncology. The Geel production site is the largest chemical API site within Johnson & Johnson and employs +800 passionate professionals. A high-tech production site for the launch of new products and the commercial production of mature products. Since 2011 we launched ZYTIGA® (prostate cancer), EDURANT® (HIV), INVEGA® SUSTENNA®/XEPLION® (schizophrenia), SIRTURO™ (tuberculosis), INVOKANA® (type 2 diabetes), and OLYSIO™ (hepatitis C).

## PHARMACEUTICAL SUPPLY CHAIN BEERSE


Janssen Supply Chain Beerse is a pharmaceutical production site where products are formulated and packed to send to the distribution centers. The Active Pharmaceutical Ingredients (API) are converted into liquids and creams, transdermals, parenterals, pellets, aseptic eye drops. Beerse masters complexity in producing more than 50 different pharmaceutical and consumer products in support of 5 different therapeutic areas. The production site has a strong track record in delivering supply chain solutions thanks to a unique combination of proximity to Research & Development, a diverse technology background and a highly skilled and flexible work force.



## Market Access

The Market Access group is committed to leading fundamental change in the way that diseases are managed. In our absolute commitment to patients, we will bring innovative, integrated healthcare solutions that will restore and extend quality of life, while creating economic value for society and our company. Working side-by-side with healthcare stakeholders and building on our people's talent we aim to build from our position of strength to demonstrate real value by delivering outcomes. This will enable us to grow and bring transformational medical innovations to even more patients. It will also enable us to become a true partner to healthcare systems and earn even more respect and trust.

Medicines + Diagnostics  
= Better Outcome for the Patient



Janssen Pharmaceutica NV  
Turnhoutseweg 30  
2340 Beerse - Belgium

Responsible Publisher: Tim De Kegel, Turnhoutseweg 30, 2340 Beerse - Belgium